Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00505219
Other study ID # ABI 55-0705-1
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2007
Est. completion date December 2010

Study information

Verified date October 2019
Source Vericel Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if Ixmyelocel-T grafting with demineralized bone matrix bound in autologous plasma after core decompression surgery is superior to core decompression with demineralized bone matrix bound in autologous plasma in preventing progression of osteonecrosis to a more severe disease stage (Stage II to III or higher) from the time of surgery until 24 months later, in patients with University of Pennsylvania (UPenn) Stage IIB or C disease at diagnosis.


Description:

This study is an event-driven, multi-center, prospective, independent observer-blinded, controlled, randomized Phase III clinical trial enrolling patients diagnosed with University of Pennsylvania (Steinberg) Classification Stage IIB or C osteonecrosis of the femoral head.

- The first patient group is the Treatment Group and will receive core decompression and treatment with BRCs and demineralized bone matrix bound in autologous plasma, and

- The second patient group is the Control Group and will receive core decompression and demineralized bone matrix bound in autologous plasma, without any BRCs.

- Enrollment: With an anticipated drop-out rate of 10% in up to twenty (20) sites, a total of approximately 135 patients will be enrolled and randomized to obtain 120 evaluable patients (75 for the TRC treatment group and 45 for the Control treatment group).

- Primary endpoint: The percentage of patients progressing to a more severe UPenn disease stage (Stage II to III or higher) between 0 and 24 months will be the primary efficacy variable to demonstrate TRC therapy is superior to Control therapy.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date December 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- UPenn (Steinberg) classification of osteonecrosis, inclusive of Stages IIB and IIC. Diagnosis will be based on magnetic resonance imaging (MRI).

- Modified index of necrotic extent < 40

- Idiopathic and non-idiopathic osteonecrosis.

- No infection in affected bones at the time of surgery.

- Patient competent to give informed consent.

- Normal organ and marrow function defined as:

- Leukocytes = 3000/µL;

- Absolute neutrophil count = 1500/µL;

- Platelets = 140,000/µL;

- Serum AST (SGOT)/ALT (SGPT) < 2.5 X institutional standard range;

- Serum creatinine within normal limits, based on clinical laboratory normal range.

- Female patients not pregnant or lactating.

- Patients with a history of corticosteroids or on active therapy, will only be eligible for enrollment if corticosteroid use is suspended for 1 month prior and 6 months after cell therapy and surgery.

- Patients who have been treated with oral bisphosphonates are eligible for the trial if treatment was stopped at least 6 months prior to enrollment.

Exclusion Criteria:

- Stages IA, IB, IC, IIA, IIIA or more severe femoral head osteonecrosis, primarily based on diagnosis by MRI.

- Flattening of the femur head (UPenn Stage IV) or articular cartilage collapse at the time of core decompression surgery.

- Septic arthritis; stress fracture, or non-osteonecrosis metabolic bone diseases (e.g., Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism, fibrous dysplasia [monostotic, polyostotic McCune-Albright syndrome] and osteopetrosis).

- Any active bisphosphonate treatment or any history of intravenous (IV) treatment

- HIV, syphilis, positive at time of screening.

- Active hepatitis B or hepatitis C infection at the time of screening

- Known allergies to protein products (horse or bovine serum, or porcine trypsin).

- Patients who will require continuous, systemic, high dose corticosteroid therapy (more than 7.5 mg/day) within 6 months after surgery.

- Patients in active treatment for cancer or blood dyscrasia, or have received chemotherapy, radiotherapy or immunotherapy in the past 2 years.

- Immunodeficiency diseases.

- Participation in another clinical study in the past 30 days or concurrent participation in another clinical trial.

- History of regular alcohol consumption exceeding 2 drinks/day (1 drink = 5 oz [150 mL] of wine or 12 oz [360 mL] of beer or 1.5 oz [45 mL] of hard liquor) within 6 months of screening and/or history of illicit drug use.

- MRI-incompatible internal devices (pacemakers, aneurysm clips, etc)

- Body mass index (BMI) of 40 Kg/m2 or greater

- Patients unable to tolerate general anesthesia defined as an American Society of Anesthesiologists (ASA) criteria of > 2

- Patients with poorly controlled diabetes mellitus (HbA1C > 8%), or with peripheral neuropathy, or known concomitant vascular problems.

- Patients receiving treatment with hematopoietic growth factors or anti-vasculogenesis or anti-angiogenesis treatment

- Traumatic osteonecrosis

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Ixmyelocel-T
Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
Other:
Standard of Care Only
Core decompression of the femoral head to remove necrotic tissue

Locations

Country Name City State
United States Sinai Hospital of Baltimore Baltimore Maryland
United States Lutheran Medical Center Brooklyn New York
United States University of Minnesota Department of Orthopaedic Surgery Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Vericel Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The progression of patients with UPenn Stage IIB or IIC disease to a more severe stage based on all available x-ray and MRI imaging. Patients who have a definitive procedure but do not have a valid assessment will be considered to have progressed. 24 months
Secondary Time to progression (in months) 24 months
Secondary Osteonecrosis volume measured by MRI 24 months
Secondary Pain and quality of life questionnaires 24 months
See also
  Status Clinical Trial Phase
Terminated NCT04072055 - MOTO Post-marketing Surveillance Study
Terminated NCT02941666 - Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip
Terminated NCT01763684 - Oxford Signature vs. Conventional Global Study N/A
Withdrawn NCT02632903 - Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study Phase 2
Active, not recruiting NCT01458782 - ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee N/A
Completed NCT01583465 - Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty N/A
Active, not recruiting NCT04401267 - Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma Phase 2
Completed NCT03197623 - Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids Phase 1
Active, not recruiting NCT05283148 - Sickle Cell Disease (SCD) Bone Pain Study N/A
Completed NCT05684588 - Post-COVID-19 Sequelae: Osteonecrosis of Femoral Head N/A
Terminated NCT03269409 - Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis Phase 1
Completed NCT00913679 - A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty N/A
Enrolling by invitation NCT02893293 - Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Phase 4
Completed NCT01345097 - A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Phase 4
Recruiting NCT00260897 - Molecular Genetic Study of Avascular Necrosis of the Femoral Head N/A
Not yet recruiting NCT06016634 - Alendronate for Osteonecrosis in Adults With Sickle Cell Disease Phase 2
Completed NCT02077647 - Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee
Recruiting NCT01619124 - Osteonecroses in Pediatric Patients With ALL N/A
Completed NCT02458937 - Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis
Recruiting NCT02661139 - Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction